Angola Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2356163
  • December 2012
  • Region: Angola
  • 42 pages
  • Business Monitor International
1 of 4

BMI View: Angola’s general election in late August 2012 brought few changes to the country’s political scene, with incumbent President Dos Santos securing a comfortable victory. Fears of civil unrest were unfounded, and for current and potential investors, Dos Santos’ re-election will ensure political stability and continuity. Consequently a ‘business-as-usual’ attitude exists. The election results have not altered our market forecasts for Angola’s healthcare and pharmaceutical market. While we expect that there will be an increase in public spending on healthcare initiatives in the short term as the government attempts to fulfil electoral promises, this will be short lived. Angola relies on international investment to fund much of its healthcare development, with Cuba an important contributor, as well as international agencies, such as Unicef, which funded a tetanus vaccination campaign in July 2012. Angola is burdened by both communicable and non-communicable diseases.

Headline Expenditure Forecasts:

- Pharmaceuticals: AOA26.78bn (US$286mn) in 2011 to AOA30.53bn (US$325mn) in 2012;
+14.0% in local currency and +13.9% in US dollar READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary 5

SWOT Analysis 7

Angola Pharmaceuticals And Healthcare SWOT 7

Pharmaceutical Risk/Reward Ratings 8
Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113 8

Rewards 9

Risks 10

Market Summary 11

Regulatory Regime 13

Intellectual Property Issues 13

Pricing And Reimbursement 13

Regulatory Developments 14

Epidemiology 14

Clinical Trials Sector 17

Industry Forecast Scenario 18

Overall Market Forecast 18
Table: Pharmaceutical Sales Indicators, 2008-2016 19

Key Growth Factors – Industry 20
Table: Healthcare Expenditure Indicators, 2008-2016 22
Table: Healthcare Governmental Indicators, 2008-2016 22
Table: Healthcare Private Indicators, 2008-2016 23

Key Growth Factors – Macroeconomic 24
Table: Angola – Economic Activity 27

Key Risks To our Forecast Scenario 28

Competitive Landscape 29

Company Developments 29

Company Profiles 31

Demographic Outlook 32
Table: Angola's Population By Age Group, 1990-2020 ('000) 33
Table: Angola's Population By Age Group, 1990-2020 (% of total) 34
Table: Angola's Key Population Ratios, 1990-2020 35
Table: Angola's Rural And Urban Population, 1990-2020 35

Glossary 36

BMI Methodology 38

How We Generate Our Pharmaceutical Industry Forecasts 38

Risk/Reward Ratings Methodology 39

Ratings Overview 39
Table: Pharmaceutical Business Environment Indicators 40

Weighting 41
Table: Weighting Of Components 41

Note: Product cover images may vary from those shown
3 of 4

Company Profiles

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.